Sacramento Bee

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals ...
WRBL

Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea

256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / ...
WTEN

Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

SAN FRANCISCO, CA / ACCESSWIRE / February 21, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment has reached approximately 75% in the ...
Nasdaq

A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy ...

Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea SAN ...